Clinical trial
A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)
NCT00394186 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00394186 |
|---|---|
| Title | A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the Beta-3-Adrenergic Receptor Agonist Solabegron in Subjects With Irritable Bowel Syndrome |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome (IBS) |
| Intervention type | Drug |
| Interventions | GW427353, Placebo |
| Enrollment | 100 |
| Start date | Aug 1, 2006 |
| First posted | Oct 31, 2006 |
| Last update posted | May 18, 2009 |
| Countries | Australia, France, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: